Tuesday, April 19, 2016

BRIEF-Corvus Pharmaceuticals announce results of preclinical studies

* Corvus Pharmaceuticals announces results of preclinical

studies demonstrating enhanced immune responses and anti-tumor

activity with CPI-444, an investigational immuno-oncology

therapy

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)